Investigators studied the effects of the H3 K27M mutation, and revealed its impact on mutations that are known drivers of DIPGs.
Read about the newly identified subset of helper T 17 immune cells that suggest a novel approach for taming chronic inflammation.
Scientific discovery by
St. Jude group could lead to new pathway for cancer treatment and understanding of ALS.
The 2018 annual meeting of the American Society of Hematology will include research from
St. Jude that stretches from the laboratory to the clinic.
St. Jude scientists and clinicians highlighted at the annual American Society of Hematology in San Diego. Read the latest.
The Public Resource of Patient-derived and Expanded Leukemias (PROPEL) offers patient-derived xenograft samples free of charge for researchers worldwide.
A surprising mechanism that might explain how the Hippo signaling pathway promotes solid tumor growth.
Common genetic variations may help find female childhood cancer survivors at increased risk of breast cancer and who are candidates for stepped up screening.
Children with ALL gain weight during treatment, and researchers suggest that early interventions should be considered.
Read how a discovery in bacteria in the 1980s led to a promising new class of compounds for treatment of PKAN, a progressive neurodegenerative disease.
Presentations outline data from Genomes for Kids study, proving clinical utility of multi-platform genome sequencing for pediatric precision oncology.
Including whole-genome sequencing into clinical genomic testing found cancer-driving mutations other sequencing methods failed to identify.
The funding will support CPIC, which provides guidelines to help clinicians understand how genetic test results should be used to optimize drug therapy.
New global childhood cancer effort aims to cure at least 60 percent of children with six of the most common kinds of cancer worldwide by 2030.
St. Jude scientists have discovered a link between sepsis during cancer treatment and long-term neurocognitive dysfunction.
Evidence suggests liquid phase separation, a process that explains why oil and water separate, may contribute to cancer, including prostate cancer.
The research will aid basic understanding of brain development, and also help understanding cellular origins of brain disorders caused by errors in development.
Geneticists discovered that mTORC3 aids cancers' resistance to rapamycin and related drugs, offering the promise of new drug therapies to treat cancers.
Read the latest on the roots of mixed phenotype acute leukemia (MPAL), including how the findings might affect treatment of patients with the high-risk cancer.
Flu infections pose a significant risk to infants. Read about the T cells the immune system relies on to repair lung damage in infants infected with influenza.
Read about what happened when researchers looked beyond mutations to understand the developmental origins and vulnerabilities of rhabdomyosarcoma.
St. Jude is the first and only NCI-designated Comprehensive Cancer Center that is devoted solely to children.
St. Jude investigators find that cognitive impairment and physical performance limitations are strong predictors of non-independence in survivors.
Financial hardship is widespread among childhood cancer survivors, reducing their quality of life and leaving them at risk for depression, other problems.
Researchers identify mutations responsible for an inherited bone marrow disorder and evidence some affected patients may regain normal immune function without treatment.
The partnership with Institute for Health Metrics and Evaluation will provide more accurate estimates of the global burden of cancer among children.
Metabolic activity in immune cells influences the fate of developing T cells, including a protein complex that plays a decisive role.
Surveys from the Childhood Cancer Survivor Study found that a surprisingly high number of survivors showed a lack of concern for their future well-being.
Researchers have applied a new way to trigger medulloblastoma in neural cells that will lead to the ability to test a promising class of anti-tumor drugs.
Under Downing’s leadership,
St. Jude has increased employee feedback channels and forums, resulting in more innovation and connectivity across the Memphis-based campus.
Check out a new algorithm that is available at no cost to help researchers get the most out of single-cell RNA sequencing technology.
Joint statement empowers parents, young adults and physicians to act to increase vaccination rates and screenings to eliminate HPV-related cancers
Study found ethanol-lock therapy failed to prevent new or recurring infections in cancer patients with central venous catheters and led to more complications.
St. Jude experts share pediatric oncology and survivorship research at the annual meeting of the American Society of Clinical Oncology.
Read about the algorithm that helped researchers uncover hidden drivers of immune regulation and production of anti-tumor T cells.
Hospital invests more than $100 million to improve childhood cancer survival rates worldwide.
For a subset of the youngest patients with the brain tumor medulloblastoma, less aggressive therapy was associated with better long-term survival.
The protein called BOK offers another target for drugs to selectively trigger apoptosis.
St. Jude is partnering with WHO to develop strategies that strengthen the global resources, organization and planning needed to identify and treat pediatric cancer.
Researchers created the first genetic screening guidelines for medulloblastoma patients after identifying gene variations that make carriers susceptible.
Using combination therapy for flu, a new class of drug offers potential for multi-drug therapy and possibly improved influenza-fighting drugs.
A family’s history of childhood leukemia leads to the discovery of a fourth gene (IKZF1) that predisposes carriers to pediatric acute lymphoblastic leukemia.
Explore research and resources by
St. Jude at the annual meeting of the American Association for Cancer Research (AACR) in Chicago.
St. Jude to offer next-generation sequencing data and analysis tools to accelerate research and cures for life-threatening pediatric diseases.
What explains cognitive problems in childhood leukemia survivors treated with chemotherapy alone? The answer may be a surprise.
Read about the molecule (IRF8) that is essential for launching an optimal immune response to Salmonella, Pseudomonas and related bacteria.
The immune system is full of surprises. Here is one about a kinase that plays an unexpected role in regulating inflammation and cell death in myeloid cells.
St. Jude scientists have demonstrated in model studies that the neurological disease spinal bulbar muscular atrophy (SBMA) can be successfully treated with drugs.
Researchers have developed a new method to measure social networks of adolescent and young adult cancer survivors. What they found might surprise you.
Millions of people have lost their hearing due to noise, chemotherapy, age or other insults. Read about efforts to help prevent such losses in the future.
A little disorder is helpful sometimes. Read how an intrinsically disordered region of the protein Bcl-xL helps cells integrate messages regarding apoptosis.
The most comprehensive look ever across the genomic landscape of childhood cancer reinforces the need for precision medicine to treat pediatric cancer.
War in Syria sent refugees flooding into Lebanon. Read about the life-saving effort to deliver effective treatment to refugee children with cancer.
Partnership established to analyze and store pediatric cancer genomics data, support data sharing and encourage greater collaboration among scientists worldwide.
St. Jude researchers reveal importance of nucleophosmin during liquid-liquid phase separation and the proteins’ role in the structure of the nucleolus.
The advanced research center builds on the
St. Jude legacy of innovations for understanding and treating childhood cancer and other life-threatening diseases.
St. Jude recognized for having exceptional workplace culture based upon employee surveys and an in-depth questionnaire.
Researchers used a new method to model the cancer genome in 3-D and show how the c-MYC oncogene drives high-risk neuroblastoma in some patients.
Mutz will play a key role in the
St. Jude Strategic Plan and future hospital expansion.
Quality improvement effort shows the way to enhance vaccination among health care providers and protect patients.
St. Jude researchers pinpoint the cell type that turns malignant in rhabdomyosarcoma, which could open the path for better treatments.
Read about the TP53 gene variations that leave young people more likely to develop acute lymphoblastic leukemia and to die as a result.